Confirmed Keynote Speakers
Nancy McWilliams
Nancy McWilliams, Ph.D., ABPP., is emerita visiting professor at the Graduate School of Applied and Professional Psychology at Rutgers University. She has written on personality and psychotherapy.
McWilliams is a psychoanalytic/dynamic author, teacher, supervisor, and therapist. She has a private practice in psychotherapy and supervision in Lambertville, New Jersey. She is a former president of the Division of Psychoanalysis of the American Psychological Association (APA).
In 2011, the American Psychological Association chose her to represent psychoanalytic therapy in the remake of the classic film, Three Approaches to Psychotherapy. She is a member of the Center for Psychotherapy and Psychoanalysis of New Jersey and an Honorary Member of the American Psychoanalytic Association, the Moscow Psychoanalytic Society, the Institute for Psychoanalytic Therapy in Turin, Italy, and the Warsaw Scientific Association for Psychodynamic Psychotherapy. Her writings have been translated into 20 languages,and she has taught in 30 countries.
Her areas of specialty include psychoanalytic theories, individual differences, personality, the relationship between psychological diagnosis and treatment, alternatives to DSM diagnostic conventions, integration of feminist theory and psychoanalytic knowledge, and the application of psychoanalytic understanding to the problems of diverse clinical populations.
Justin Baker
Justin T. Baker, MD, PhD, is the scientific director of the McLean Institute for Technology in Psychiatry (ITP) and director of the Laboratory for Functional Neuroimaging and Bioinformatics at McLean Hospital. He is also an associate professor of psychiatry at Harvard Medical School.
Dr. Baker’s research uses both large-scale studies and deep, multilevel phenotyping approaches to understand the nature and underlying biology of mental illnesses. He is a clinical psychiatrist with expertise in schizophrenia and bipolar spectrum disorders and other disorders of emerging adulthood. In 2016, Dr. Baker co-founded the ITP, a first-of-its-kind research and development center to foster tool development and novel applications of consumer technology in psychiatric research and care delivery.
Robert Gregory
Dr. Robert Gregory has earned both national and international recognition for his ground-breaking clinical work with patients who suffer from treatment-resistant borderline personality disorder. The treatment he developed, Deconstructive Dynamic Psychotherapy (DDP), is one of the first types of psychodynamic psychotherapy to be listed on the Substance Abuse and Mental Health Services Administration (SAMHSA) National Registry of Evidence-based Practices and Programs. One of the internationally acclaimed researchers in this field, Dr Bateman, writes that "his ideas are innovative because he is trying to link specific neuro-cognitive functions that form the basis for a coherent sense of self with the pathology of borderline personality disorder. There are few people who link neuroscience through to clinical practice."
Ken Levy
Ken Levy is a broadly trained clinical psychologist whose research interests bridge the areas of social, personality, and developmental psychology. His research focuses on attachment theory, emotion regulation, personality disorders, and psychotherapy process and outcome. Recent projects have examined the relationship of the content and structure of mental representations and adult attachment neurocognitive functioning and neural activity and emotion regulation in borderline personality disorder, and psychotherapy outcome in the treatment of personality disorders. Current projects examine mechanisms of change in psychotherapy for borderline personality disorder, the contextual and personality factors that influence post-treatment adjustment in patients with borderline personality disorder, the influence of attachment and representation on stress reactivity in patients with borderline personality disorder, and the developmental precursors of personality problems in children of parents with personality disorders. He and his students pursue this research in their laboratory at Penn State and also in collaboration with colleagues at the New York Presbyterian Hospital/Cornell Medical Center.
Brandon Unruh
Brandon Unruh, MD, is the medical director of the Gunderson Residence, an intensive, specialized residential program for women with severe personality disorders. His clinical approach is anchored in the integration of evidence-based treatments such as dialectical behavior therapy, mentalization-based treatment, and general psychiatric management.
Dr. Unruh came to a career in psychiatry and psychotherapy through interests in literature and philosophy, as well as science. He has published on a variety of topics including medical ethics, general hospital psychiatry, and literature and medicine. His academic interests also include the examination of philosophical and spiritual issues from psychiatric and psychoanalytic perspectives.
John Torous
John Torous, MD MBI, is director of the digital psychiatry division in the Department of Psychiatry at Beth Israel Deaconess Medical Center (BIDMC), a Harvard Medical School-affiliated teaching hospital, where he also serves as a staff psychiatrist and assistant professor. He has a background in electrical engineering and computer sciences and received an undergraduate degree in the field from UC Berkeley before attending medical school at UC San Diego. He completed his psychiatry residency, fellowship in clinical informatics, and master's degree in biomedical informatics at Harvard. Dr. Torous is active in investigating the potential of mobile mental health technologies for psychiatry and has published over 300 peer reviewed articles and 5 book chapters on the topic. He directs the Digital Psychiatry Clinic at BIDMC which seeks to improve access to and quality of mental health care through augmenting treatment with digital innovations. Dr. Torous serves as editor-in-chief for the journal JMIR Mental Health, web editor for JAMA Psychiatry, and is a member of the FDA Digital Health Advisory Committee.